Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SCN7A | Q01118 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810249 | 0.87 | SCN9A (0.51) | SCN9AHRH3SCN7AKCNH2 | |
| SCHEMBL12188601 | 0.85 | GAA (0.49) | GAA | |
| SCHEMBL1809041 | 0.85 | SCN9A (0.50) | SCN9AHRH3GAASCN7AKCNH2 | |
| SCHEMBL12188766 | 0.79 | SPR (0.44) | GAA | |
| SCHEMBL1807553 | 0.74 | SCN9A (0.47) | SCN9AGAASCN7AKCNH2 | |
| SCHEMBL1808456 | 0.73 | HRH3 (0.66) | SCN9AHRH3GAASCN7AKCNH2 | |
| SCHEMBL1808016 | 0.73 | HRH3 (0.66) | SCN9AHRH3GAASCN7AKCNH2 | |
| SCHEMBL1811165 | 0.71 | CCKAR (0.40) | SCN9AHRH3PRKAA2 | |
| SCHEMBL1809328 | 0.70 | SMN1; SMN2 (0.50) | SCN9AGAASCN7AKCNH2 | |
| SCHEMBL15103527 | 0.70 | CACNA1B (0.60) | SCN9ASCN7AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | SCN9A 20/4885HRH3 1010/4885GAA 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.